These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

49 related items for PubMed ID: 8555648

  • 1. The steroidogenic and morphological effects of paclitaxel on cultured ovarian cancer cells.
    Cameron MR, Caudle MR, Sullivan WR, Peluso JJ, Wimalasena J.
    Oncol Res; 1995; 7(3-4):145-56. PubMed ID: 8555648
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF.
    BMC Cancer; 2006 Jul 11; 6():183. PubMed ID: 16834771
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.
    Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST, Chang TC, Wang HS.
    Oncogene; 2006 Aug 10; 25(35):4857-66. PubMed ID: 16547493
    [Abstract] [Full Text] [Related]

  • 5. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 6. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
    Belotti D, Rieppi M, Nicoletti MI, Casazza AM, Fojo T, Taraboletti G, Giavazzi R.
    Clin Cancer Res; 1996 Oct 15; 2(10):1725-30. PubMed ID: 9816123
    [Abstract] [Full Text] [Related]

  • 7. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
    Law KS, Chen HC, Liao SK.
    Anticancer Res; 2007 Oct 15; 27(2):841-50. PubMed ID: 17465210
    [Abstract] [Full Text] [Related]

  • 8. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
    Kim SH, Juhnn YS, Song YS.
    Ann N Y Acad Sci; 2007 Jan 15; 1095():82-9. PubMed ID: 17404021
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro.
    Jaime J, Pagé M.
    Anticancer Res; 2001 Jan 15; 21(2A):1119-28. PubMed ID: 11396150
    [Abstract] [Full Text] [Related]

  • 10. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
    Lamendola DE, Duan Z, Yusuf RZ, Seiden MV.
    Cancer Res; 2003 May 01; 63(9):2200-5. PubMed ID: 12727840
    [Abstract] [Full Text] [Related]

  • 11. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A, Soprano DR, Parekh HK.
    Cancer Res; 2001 Oct 15; 61(20):7552-5. PubMed ID: 11606393
    [Abstract] [Full Text] [Related]

  • 12. The range of optimal concentration and mechanisms of paclitaxel in radio-enhancement in gastrointestinal cancer cell lines.
    Toiyama Y, Inoue Y, Hiro J, Ojima E, Watanabe H, Narita Y, Hosono A, Miki C, Kusunoki M.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):733-42. PubMed ID: 16957932
    [Abstract] [Full Text] [Related]

  • 13. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
    Gooch JL, Lee AV, Yee D.
    Cancer Res; 1998 Sep 15; 58(18):4199-205. PubMed ID: 9751635
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.
    Au JL, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh HJ, Chen CT, Wientjes MG.
    Cancer Res; 1998 May 15; 58(10):2141-8. PubMed ID: 9605758
    [Abstract] [Full Text] [Related]

  • 16. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients.
    Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C.
    Gynecol Oncol; 2000 Mar 15; 76(3):326-30. PubMed ID: 10684705
    [Abstract] [Full Text] [Related]

  • 17. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E.
    Mol Pharmacol; 1997 Oct 15; 52(4):613-22. PubMed ID: 9380024
    [Abstract] [Full Text] [Related]

  • 18. Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
    Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, Tsiftsis DD, Theodoropoulos PA.
    Ann Surg Oncol; 2007 Mar 15; 14(3):1220-8. PubMed ID: 17206477
    [Abstract] [Full Text] [Related]

  • 19. Endometrial cancer cell lines are sensitive to paclitaxel.
    Rantanen V, Grénman S, Kulmala J, Grénman R.
    Anticancer Res; 1996 Mar 15; 16(1):475-9. PubMed ID: 8615657
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Hata K, Osaki M, Dhar DK, Nakayama K, Fujiwaki R, Ito H, Nagasue N, Miyazaki K.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):68-74. PubMed ID: 14569416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.